Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Comparative cost-effectiveness analysis of oral triptan therapy for migraine in four European countries.

Hens M, Villaverde-Hueso A, Alonso V, Abaitua I, Posada de la Paz M.

Eur J Health Econ. 2014 May;15(4):433-7. doi: 10.1007/s10198-013-0516-x. Epub 2013 Jul 10.

PMID:
23839914
2.

A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy.

Gori S, Morelli N, Acuto G, Caiola F, Iudice A, Murri L.

Minerva Med. 2006 Dec;97(6):467-77.

PMID:
17213783
3.

Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.

Runken MC, Goodwin B, Shah M, Eaddy M, D'Souza A, Bowers B, Bell CF.

Appl Health Econ Health Policy. 2015 Feb;13(1):109-20. doi: 10.1007/s40258-014-0129-2.

PMID:
25294555
4.

Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.

Mullins CD, Subedi PR, Healey PJ, Sanchez RJ.

Pharmacotherapy. 2007 Aug;27(8):1092-101.

PMID:
17655509
5.
6.

The use of triptans for pediatric migraines.

Eiland LS, Hunt MO.

Paediatr Drugs. 2010 Dec 1;12(6):379-89. doi: 10.2165/11532860-000000000-00000. Review.

PMID:
21028917
7.

[Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal].

Félix JM, Inês MS, Acosta CM.

Acta Med Port. 2005 Jan-Feb;18(1):77-87. Epub 2005 Mar 11. Portuguese.

10.

Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison.

Asseburg C, Peura P, Oksanen T, Turunen J, Purmonen T, Martikainen J.

Int J Technol Assess Health Care. 2012 Oct;28(4):382-9. doi: 10.1017/S0266462312000517. Epub 2012 Sep 26.

PMID:
23013610
11.

The cost-effectiveness of oral triptan therapy in Sweden.

Ramsberg J, Henriksson M.

Cephalalgia. 2007 Jan;27(1):54-62.

PMID:
17212684
12.
13.

Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine.

Williams P, Reeder CE.

Clin Ther. 2003 Nov;25(11):2903-19.

PMID:
14693315
14.
15.

Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms.

Mannix LK, Adelman JU, Goldfarb SD, Von S, Kozma CM.

Am J Manag Care. 2002 Feb;8(3 Suppl):S94-101. Review.

16.

[Economic evaluation of acute migraine attack treatment with triptans in Spain].

Gracia-Naya M, Rejas Gutiérrez J, Latorre Jiménez A, González Garcia P.

Neurologia. 2005 Apr;20(3):121-32. Spanish.

PMID:
15815947
17.

Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan.

Wang JT, Barr CE, Goldfarb SD.

Headache. 2002 Jan;42 Suppl 1:38-43.

PMID:
11966863
18.

Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy.

Kelman L, Von Seggern RL.

Am J Ther. 2006 Sep-Oct;13(5):411-7. Review.

PMID:
16988536
19.

Cost-effectiveness analysis of burning mouth syndrome therapy.

Hens MJ, Alonso-Ferreira V, Villaverde-Hueso A, Abaitua I, Posada de la Paz M.

Community Dent Oral Epidemiol. 2012 Apr;40(2):185-92. doi: 10.1111/j.1600-0528.2011.00645.x. Epub 2011 Nov 1.

PMID:
22044166
20.

Supplemental Content

Support Center